Emergent BioSolutions Inc. (NYSE:EBS) Stock Holdings Boosted by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. boosted its position in Emergent BioSolutions Inc. (NYSE:EBS) by 3.4% during the 4th quarter, HoldingsChannel reports. The firm owned 766,537 shares of the biopharmaceutical company’s stock after buying an additional 24,985 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Emergent BioSolutions were worth $7,328,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. SeaCrest Wealth Management LLC increased its stake in shares of Emergent BioSolutions by 3.2% in the third quarter. SeaCrest Wealth Management LLC now owns 118,700 shares of the biopharmaceutical company’s stock valued at $991,000 after purchasing an additional 3,705 shares during the period. Stifel Financial Corp bought a new position in Emergent BioSolutions in the 3rd quarter worth approximately $96,000. FORA Capital LLC acquired a new stake in Emergent BioSolutions in the 3rd quarter valued at approximately $103,000. Hilltop Holdings Inc. raised its stake in Emergent BioSolutions by 7.9% during the 3rd quarter. Hilltop Holdings Inc. now owns 171,266 shares of the biopharmaceutical company’s stock valued at $1,430,000 after acquiring an additional 12,515 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in Emergent BioSolutions during the 2nd quarter worth $93,000. 78.40% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on EBS. StockNews.com raised Emergent BioSolutions from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Benchmark raised their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Emergent BioSolutions in a research note on Friday, January 10th.

Emergent BioSolutions Price Performance

Shares of Emergent BioSolutions stock opened at $9.91 on Monday. Emergent BioSolutions Inc. has a 52 week low of $1.42 and a 52 week high of $15.10. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The stock has a market cap of $536.69 million, a PE ratio of -2.42 and a beta of 1.60. The company’s 50-day moving average price is $9.31 and its two-hundred day moving average price is $9.23.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.